Drug Interaction Report

ADJUST DOSING INTERVAL: Coadministration of revakinagene taroretcel ophthalmic with drugs that can affect hemostasis such as anticoagulants, platelet inhibitors, thrombin inhibitors, thrombolytic agents, dextrans, and nonsteroidal anti-inflammatory drugs (NSAIDs) may increase the risk of vitreous hemorrhage, which may result in temporary vision loss.

MANAGEMENT: The manufacturer of revakinagene taroretcel ophthalmic recommends temporarily interrupting antithrombotic medications before revakinagene taroretcel implantation. Patients should be advised to promptly report any signs of blurred vision, vision loss, floaters, or flashes of light. Clinicians should consult relevant literature, local and national treatment guidelines, and package labeling for further guidance.

GENERALLY AVOID: The concurrent use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs) and ethanol may lead to gastrointestinal (GI) blood loss. The mechanism may be due to a combined local effect as well as inhibition of prostaglandins leading to decreased integrity of the GI lining.

MANAGEMENT: Patients should be counseled on this potential interaction and advised to refrain from alcohol consumption while taking aspirin or NSAIDs.